18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse

被引:30
作者
Sanchez, D [1 ]
Zudaire, JJ [1 ]
Fernandez, JM [1 ]
Lopez, J [1 ]
Arocena, J [1 ]
Sanz, G [1 ]
Gimenez, M [1 ]
Rosell, D [1 ]
Robles, JE [1 ]
Berian, JM [1 ]
机构
[1] Univ Navarra, Clin Univ, Fac Med, Dept Urol, Pamplona 31007, Spain
关键词
nonseminomatous germ cell tumour; positron emission tomography; fluorodeoxyglucose; computed tomography;
D O I
10.1046/j.1464-410X.2002.02779.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To compare the performance of F-18-fluoro2-deoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) in the follow-up of nonseminomatous germ cell tumours (NSGCT) in the retroperitoneum. Patients and methods FDG-PET was used 25 times in 15 patients diagnosed with NSGCT. At the time of diagnosis five patients each were in stage I, II and III. Five patients had pure embryonal carcinoma. two had Yolk Sac tumours, one choriocarcinoma and seven had mixed tumours. Results Eleven patients either presented with retroperitoneal disease or this did not disappear after chemotherapy. The results of both examinations coincided in 18 cases and were contradictory in the other seven, the difference being statistically significant (P=0.042). Conclusion In these patients FDG-PET detected the retroperitoneal relapse of NSGCT. in advanced stages treated with surgery plus chemotherapy, earlier than did CT: it also detected the presence of mature teratoma in residual retroperitoneal masses more accurately than CT. More extensive trials are needed before making conclusions about FDG-PET imaging as a routine method for NSGCT.
引用
收藏
页码:912 / 916
页数:5
相关论文
共 18 条
[1]   Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors [J].
Albers, P ;
Bender, H ;
Yilmaz, H ;
Schoeneich, G ;
Biersack, HJ ;
Mueller, SC .
UROLOGY, 1999, 53 (04) :808-811
[2]   Testicular germ-cell cancer [J].
Bosl, GJ ;
Motzer, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04) :242-253
[3]  
CEMERIUS U, 1999, UROLOGY, V54, P900
[4]   Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand [J].
Colls, BM ;
Harvey, VJ ;
Skelton, L ;
Frampton, CMA ;
Thompson, PI ;
Bennett, M ;
Perez, DJ ;
Dady, PJ ;
Forgeson, GV ;
Kennedy, ICS .
BJU INTERNATIONAL, 1999, 83 (01) :76-82
[5]   TREATMENT OF TESTICULAR CANCER - A NEW AND IMPROVED MODEL [J].
EINHORN, LH .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (11) :1777-1781
[6]  
EINHORN LH, 1981, CANCER, V48, P904, DOI 10.1002/1097-0142(19810815)48:4<904::AID-CNCR2820480407>3.0.CO
[7]  
2-O
[8]   RETROPERITONEAL IMAGING WITH 3RD AND 4TH GENERATION COMPUTED AXIAL-TOMOGRAPHY IN CLINICAL STAGE-I NONSEMINOMATOUS GERM-CELL TUMORS [J].
FERNANDEZ, E ;
MOUL, JW ;
FOLEY, JP ;
COLON, E ;
MCLEOD, DG .
UROLOGY, 1994, 44 (04) :548-552
[9]   Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma [J].
Ganjoo, KN ;
Chan, RJ ;
Sharma, M ;
Einhorn, LH .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3457-3460
[10]   Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse [J].
Hain, SF ;
O'Doherty, MJ ;
Timothy, AR ;
Leslie, MD ;
Harper, PG ;
Huddart, RA .
BRITISH JOURNAL OF CANCER, 2000, 83 (07) :863-869